"ProSomnus delivered record revenues, significant revenue growth and strong organizational execution in the second quarter of 2023," said Len Liptak, Chief Executive Officer. "The rapidly increasing ...
Obstructive Sleep Apnea treatment provider ProSomnus Inc OSA reported Q2 revenues of $6.9 million, up 43% Y/Y and a sequential revenue increase of 19%, slightly beating the consensus of $6.4 million.
PLEASANTON, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea ("OSA"), will report its strong second ...
PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study ...
Most of the patients mild-to-moderate patients were treated to an apnea-hypopnea index of fewer than 10 events per hour. After a minimum one-year follow-up period, 96% of patients continued using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results